

## ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the **ABSTRACT TEMPLATE** online, for Biomed 2025 Company Presentations  
All items marked with an \* are mandatory to complete  
The maximum number of words for this abstract is 400  
Please be sure to complete the following:

Company name Promise Bio Website <https://www.promise.bio/>

CTO name Ronel Veksler

**CATEGORY:** Biotech/Pharma

### SESSIONS

- **Personalized Medicine; Navigating Strategic Pathways – Pharma or Payers or Both**

You may delete the section instructions, leaving only the **bolded bullet title**  
Answers below should not exceed 60 words per question:

- **Executive Summary**

Promise Bio has developed the first broad-Epiproteomics platform to resolve intricate biological questions and enhance data-driven decision-making in drug development and clinical disease management for chronic diseases. Backed by strategic investors AstraZeneca and Pfizer and built on years of research from the Weizmann Institute of Science (Kacen et al., Nature Biotechnology 2023), the PromiseOS suite delivers end-to-end actionable, deep mechanistic insights.

- **Core Technology**

At its core, the ProSpect platform identifies over 60 post-translational modifications (PTMs) from mass spectrometry data, operating 100x faster and without chemical enrichment. These results are augmented by a proprietary, PTM-focused data lake through the EpiTome platform, applying advanced machine learning to reveal biological insights, expanding beyond what is currently possible with other omics, including protein abundance-based methods.

- **Product Profile**

The PromiseOS suite is designed to maximize the utility of our collaborators' data to unlock biomarker discovery, patient stratification, mechanism-of-action analytics, novel target discovery, indication expansion, dose optimization, and combination strategies.

- **Business Strategy**

Promise Bio collaborates with global pharmaceutical companies to support data-driven decision-making at different stages of drug development, and works with leading research institutes to drive the next frontier of precision medicine.

In addition, Promise Bio is running the first multi-center observational clinical trials to establish the most clinically relevant, deeply annotated data lake of Epiroteomics in immune-mediated diseases.

- **What's Next?**

Promise Bio plans to expand its platform across diverse data types and tissue sources, building the world's largest PTM data lake and linking epiroteomics to biological function.

We are scaling our pharma services, supporting more disease areas across drug development stages, and our continuously expanding data lake will enable building foundation models for precision medicine in immune-mediated diseases.